State of the art in mesothelioma

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Scagliotti, G V ^a   Novello, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID; GEMCITABINE; IMATINIB; OPIATE; OXYGEN; PEMETREXED; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P53; RALTITREXED; RANPIRNASE; SEMAXANIB; THALIDOMIDE; VATALANIB;

ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CPG ISLAND; DECORTICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MESOTHELIOMA; MOLECULAR BIOLOGY; NAUSEA AND VOMITING; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MESOTHELIOMA; PHARMACOGENETICS; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 21344469972     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi703     Document Type: Article

References (31)

1. Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672.
2. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-1168.
3. Tammilehto L, Maasilta P, Kostiainen S et al. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration 1992; 59: 129-135.
4. Chailleux E, Dabouis G, Pioche D et al. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988; 93: 159-162.
5. Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 1999; 14: 181-188.
6. Carbone M, Pass HI, Rizzo P et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994; 9: 1781-1790.
7. Carbone M, Rizzo P, Pass H. Simian virus 40: the link with human malignant mesothelioma is well established. Anticancer Res 2000; 20: 875-877.
8. Lopez-Rios F, Illei PB, Rusch V et al. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004; 364: 1157-1166.
9. Toyooka S, Pass I, Shivapurkar N et al. Aberrant methylation and Simian virus 40 Tag sequences in malignant mesothelioma. Cancer Res 2001; 61: 5727-5730.
10. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-140.
11. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
12. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 1995; 108: 1122-1128.
13. Patz EF Jr, Rusch VW, Heelan R. The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. Am J Roentgenol 1996; 166: 323-327.
14. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer Experience. J Clin Oncol 1998; 16: 145-152.
15. Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
16. Pass HI, Temeck BK, Kranda K et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998; 115: 310-318.
17. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990; 13: 4-9.
18. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14: 1007-1017.
19. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.
20. Nowak AK, Byrne MJ, Williamson R et al. A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-496.
21. Van Haarst, JW, Burgers, JA, Manegold, CH et al. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM). In: Program and Abstracts of the Ninth World Conference on Lung Cancer, 11-15 September 2000, Tokyo, Japan. Lung Cancer 2000; 29 (Suppl 1): 18 (Abstr 56).
22. Hughes A, Calvert, Azzobi A et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20: 3533-3544.
23. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
24. Fizazi K, Doubre H, Le Chevalier T et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003; 21: 349-354.
25. van Meerbeeck J, Manegold C, Gaafar R et al. A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the EORTC Lung Cancer Group and NCIC. Proc Am Soc Clin Oncol 2004; 22: 622s (Abstr 7021).
26. Taub RN, Keohan ML, Vogelzang NJ et al. Phase II trial of Onconase® in patients (PTS) with advanced malignant mesothelioma (MM): analysis of survival. Proc Am Soc Clin Oncol 1999; 18: 524a (Abstr 2021).
27. Vogelzang N, Taub R, Shin D et al. Phase III randomized trial of Onconase versus doxorubicin in patients with unresectable malignant mesothelioma. Analysis of survival. Proc Am Soc Clin Oncol 2000; 19: 577a (Abstr 2274).
28. Ohta Y, Shridhar V, Bright RK et al. VEGF and EGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81: 54-61.
29. Langerak AW, De Laat PAJM, Van-Der-Linden-Van Beurden CAJ et al. Expression of platelet-derived growth factor and receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996; 178: 151-160.
30. Govindan R, Kratzke RA, Herndon JE et al. Gefitinib in patients with malignant mesothelioma. A phase II study by the Cancer and Leukemia Group B (CALGB 30101). Proc Am Soc Clin Oncol 2003; 21: 630 (Abstr 2535).
31. Garland L, Rankin C, Scott K et al. Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: A phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 in patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2004; 22: 196sa (Abstr 3007).